



2024/9/30

產業類別	航運
投資建議	買進 
收盤價	目標價
NT\$ 46.40	NT\$ 58.00

本次報告：法說會

## 交易資料

潛在報酬率 (%)	25.00
52 週還原收盤價區間 (NT\$)	38.29-58.68
市值 (NT\$百萬元)	9160
市值 (US\$百萬美元)	289
流通在外股數 (百萬股)	198.00
董監持股 (%)	27.35
外資持股 (%)	2.62
投信持股 (%)	0.00
融資使用率 (%)	3.51

## 財務資料

	2023
股東權益 (NT\$百萬元)	11,584
ROA (%)	1.5
ROE (%)	2.83
淨負債比率 (%)	50.25

## 公司簡介

中航是一家從事海岬型船營運和陸運貨櫃運送的公司。1H24 海運收入佔 66%，陸運佔 33%，獲利貢獻海運佔 67%，陸運佔 32%。2023 年交 2 艘海岬型船，2024 年 8 月新增 2 艘海岬型船，目前船隊共有 14 艘海岬型船(4Q24 會處分 1 艘)，以合約船為主，船齡 8.9 年。

主要客戶：

主要競爭對手：裕民、新興

陳宜里 yili.chen@sinopac.com

## 中航 (2612 TT)

4Q 認列處分船舶利益推升獲利


### 永豐觀點

海岬型船新船下水相對較少，4Q 處分船舶利益推升獲利。

### 投資評價與建議


**建議買進：**(1) 中國鋁礬土庫存偏低，剛性需求支撐，(2) 4Q24 有處分船舶利益挹注，(3) 以配息 6 成估算配發 2.6 元，現金殖利率 5.6%，(4) 過去歷史 PBR 為 0.6-0.9 倍，目前 PBR 0.64 倍，建議買進，目標價 58 元(0.8 X 2025 BVPS)。

### 近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Sep. 2024

### 近八季營業利益及毛利率趨勢圖




資料來源：CMoney；永豐投顧研究處整理，Sep. 2024

## ✍ 營運現況與分析

**散裝航運和陸運兼併的航運公司：**中航是一家從事海岬型船營運和陸運貨櫃運送的公司，1H24 海運收入佔 66%，陸運佔 33%，獲利貢獻海運佔 67%，陸運佔 32%，2023 年交 2 艘海岬型船，2024 年 8 月新增 2 艘海岬型船，目前船隊共有 14 艘海岬型船(4Q24 會處分 1 艘)，以合約船為主，船齡 8.9 年，轉投資持有油輪為主的環能海運 12%和空運承攬商中菲行 5.55%。在手訂單有 2 艘海岬型新船預計 2H26 加入。

**9 月海岬型運價平均 2.71 萬美元/日(+28%MoM,+92%YoY)：**雖然中國鋼市疲軟但煤鐵進口需求強勁，煤炭海運進口量 3.42 億噸(+11.8%YoY)，鐵礦砂進口 8.15 億噸(+5.2%YoY)，1-8 月中國從幾內亞進口鋁礬土 7790 萬噸(+12.5%YoY)，加上今年新船下水相對去年少(2023 年交 56 艘，2024 年預計交 39 艘)，即使淡季海岬型運價走勢仍較去年高。中國調降利率帶動鐵礦砂出現明顯反彈(88 美元/噸漲到 96.5 美元)，海岬型 9/26 上漲 8%收 2.97 萬美元/日(+28%MoM)，9 月平均價格 2.71 萬美元，優於研究處預期，但中國財政政策對於帶動鋼廠搶運鐵礦砂效果有待觀察，研判對提振市場信心較多。

圖一：海岬型船現貨運費



資料來源：Bloomberg；永豐投顧研究處整理，Sep. 2024

**未來幾年海岬型船交船數量走緩：**2023 年交 56 艘海岬型船，運力淨增加 2.3%，今年以來海岬型船交船 32 艘，運力淨增加 1.4%，年底前尚有 7 艘，目前海岬型船新船在手訂單 7%，是所有船型最低的，預計 2025-2027 年分別交 38、34 和 28 艘，船舶交船數走緩。Clarkson 預估 2024 年散裝運送需求 2.2%(鐵礦砂+2.9%，煤碳+0.3%，鋁礬土+8%，穀物+4.6%)，供需結構相對穩定。

**財務預估：**預估 2024 年營收 46.8 億元(+17%YoY)，因有處分船舶利益 1280 萬美元挹注，預估稅後獲利 8.5 億元(+159%YoY)，以目前股本 19.75 億元計算，稅後 EPS 為 4.3 元，每股淨值 67.6 元。2025 年預估營收 51.4 億元(+9.8%YoY)，預估稅後獲利 6.7 億元(-20.6%YoY)，稅後 EPS 為 3.41 元，每股淨值 72.1 元。以配息 6 成估算配發 2.6 元，現金殖利率 5.6%。

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3F	24Q4F	2024F
營業收入	1,016	1,128	1,229	1,309	4,681
營業毛利	230	270	324	350	1,174
營業利益	110	155	197	220	682
稅前淨利	134	198	145	568	1,046
稅後純益	128	183	111	426	849
稅後 EPS (元)	0.65	0.93	0.56	2.16	4.3
營收 QoQ 成長率	-4.16	11.02	9.05	6.51	--
營收 YoY 成長率	9.28	14.94	17.72	23.61	16.62
毛利率	22.60	23.94	26.36	26.74	25.08
營益率	10.84	13.76	16.03	16.81	14.57
稅後純益率	12.55	16.19	9.03	32.54	18.14

資料來源：CMoney；永豐投顧研究處整理，Sep. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	3,554	4,410	4,015	4,681	5,139
%變動率	13.45	24.09	-8.96	16.59	9.78
營業毛利	774	1,385	857	1,174	1,405
毛利率 (%)	21.79	31.41	21.35	25.08	27.34
營業淨利	354	929	374	682	902
稅前淨利	1,113	841	433	1,046	765
%變動率	224.12	-24.42	-48.58	141.57	-26.86
稅後純益	1,041	766	328	849	674
%變動率	216.26	-26.38	-57.14	158.84	-20.61
稅後 EPS * (元)	5.27	3.88	1.66	4.3	3.41
市調 EPS * (元)	5.2	2.65	1.94	2.89	--
PER (x)	9.21	12.51	29.25	11.29	14.24
PBR (x)	0.92	0.82	0.83	0.71	0.67
每股淨值 * (元)	52.71	58.95	58.66	68.65	72.06
每股股利 (元)	2.68	2.18	1.00	--	--
殖利率 (%)	5.32	5.67	2.01	--	--

\* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理，Sep. 2024

## 營運基本資料


### 同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024
2605	新興	B	30.15	175.0	0.76	3.33	33.36	8.98	0.93	1.00
2606	裕民	B	55.60	471.6	3.24	4.80	16.08	11.62	1.31	1.21


### 近三年單月營收狀況




### 近三年單季營收 VS 毛利率趨勢圖



## 歷史 PE 圖



## 歷史 PB 圖



---

臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

---

#### 責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

---

#### SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

---

**Analyst Certification:**

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

**SinoPac Research Stock Rating System:**

**Buy:** We think the stock will outperform the broader market over the next 12 months.

**Neutral:** We think the stock will perform in line with the broader market over the next 12 months.

**Sell:** We think the stock will underperform the market over the next 12 months.

**Global Disclaimer:****Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

**Ownership and Material Conflicts of Interest**

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

**Compensation and Investment Banking Activities**

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

**Additional Disclosures**

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.